NEW YORK (GenomeWeb) – Serametrix, a San Diego-based company specializing in immune monitoring assays, has received CLIA certification for its laboratory in Carlsbad, California, the firm said recently.
The certification enables the company to offer its myeloid-derived suppressor cell assay for cancer patients. The flow cytometry-based assay was developed at the Ludwig Center for Cancer Immunotherapy at Memorial Sloan-Kettering Cancer Center and was licensed by Serametrix in 2013.
The test uses a patient blood sample and is intended to guide oncologists in selecting and predicting response to patient immunotherapies. It is one component of the company's icScore offering, a single-sample battery of immune-based tests for cancer patients. Also under development is a blood test for PD-L1-positive peripheral immune cells, which will be incorporated into icScore later this year, Serametrix said.